Shares shifted sharply higher in pre-market trading as Neuronetics (STIM) prepared to report second-quarter 2026 results before the opening bell. Analysts expect an adjusted loss of $0.11 per share on revenue of roughly $40.17 million — a number that, if hit, would mark a meaningful step up from Q1's $34.45 million in revenue . The stock jumped 11.1% to $2.41, clawing back Friday's 8.8% decline and then some, as traders bet on a beat-and-raise scenario.

A New Boss Faces His First Real Test

Dan Reuvers took over as CEO on March 23, bringing more than 30 years of medical-device experience. Today's call is the first full quarter under his watch, and investors will listen closely for signs he's reshaping the cost structure. In Q1, operating expenses fell 6% to $25.1 million and Adjusted EBITDA — a rough measure of operating cash generation — improved to negative $6.6 million from negative $8.6 million a year earlier. Any acceleration of that trend could shift sentiment for a stock carrying a market cap of just $166 million .

Losses Are Shrinking, but the Balance Sheet Stays Tight

Net loss narrowed to $10.8 million in Q1 from $12.7 million a year ago , yet cash plus restricted cash stood at only $19 million against $61.3 million in long-term debt.

The debt-to-equity ratio sits at 4.04, and the Altman Z-Score — a measure of bankruptcy risk — registers at negative 3.31, placing Neuronetics in the "distress zone." Investors need to hear whether the company can fund operations into 2027 without raising new capital.

Mid-Single-Digit Growth Guidance Sets a Low Bar

Management guided Q2 revenue growth in the "mid-single digits" , implying roughly $38–$40 million. Full-year guidance remains $160–$166 million with gross margins of 47%–49%. The consensus estimate of ~$40 million sits at the top of that implied range, so a beat is already partially priced in. Optum's expanded coverage of the company's brain-stimulation therapy — now reaching about 34.8 million insured lives — may boost utilization , but the real question is whether clinic patient volumes are accelerating or plateauing.

Wall Street Is Cautiously Optimistic — at Twice Today's Price

The consensus 12-month target is $4.50 , roughly double the current quote, with individual targets ranging from $3 to $7. That gap between price and target reflects both perceived upside and deep uncertainty. Today's earnings call will either begin to close that gap or widen it further.